Mumbai: Servier India on Tuesday announced a patient-centric biomarker testing initiative in partnership with MedGenome and Strand Life Sciences to improve early diagnosis and access to precision oncology testing for Acute Myeloid Leukaemia (AML) and Cholangiocarcinoma (CCA).

Under the initiative, a customized panel of biomarker tests for AML—an aggressive blood cancer—and CCA—a rare bile duct cancer—will be made available across India at subsidized rates. The IDH1 and IDH2 mutation tests for both cancers will be offered free of cost to patients in the government sector, the company said in a statement.

The initiative aims to bridge the access gap in molecular testing , which currently remains concentrated in urban areas, limiting timely and accurate diagnosis for many pati

See Full Page